Home › Compare › AIABF vs ABBV
AIABF yields 1538.46% · ABBV yields 3.06%● Live data
📍 AIABF pulled ahead of the other in Year 1
Combined, AIABF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AIABF + ABBV for your $10,000?
Capital A Berhad, an investment holding company, provides air transportation services in Malaysia, Indonesia, the Philippines, and internationally under the AirAsia brand. It also offers management, engineering, tour operating, aircraft leasing, shared and outsourcing, central depository, financial and other related, event ticketing, and consultancy services, as well as services in the areas of information technology design, development, and implementation; facilitates business transactions for AirAsia Group with non-resident goods and service providers; and trades in coffee and tea related products, and multimedia content and equipment. In addition, the company provides inflight meal products; manages customer loyalty points; wholesales meat, fish, fruits, vegetables, flowers, and plants; offers online retail sales, inflight magazine content, inflight shop, aviation and commercial, airport related, food and beverages, and research and development services, as well as supporting services to air transport; and operates AirAsia Superapp. Further, it is involved in the marketing and development of loyalty programs; development of software for cybersecurity; and provision of media content, e-hailing, online food ordering, delivery, investment management, and cargo services, as well as provides logistic and payment services for cross border e-commerce marketing. The company was formerly known as AirAsia Group Berhad and changed its name to Capital A Berhad in January 2022. Capital A Berhad was founded in 2001 and is headquartered in Kuala Lumpur, Malaysia.
Full AIABF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.